Bionano Genomics (NASDAQ:BNGO) will be posting its quarterly earnings results after the market closes on Thursday, March 9th. Analysts expect Bionano Genomics to post earnings of ($0.09) per share for the quarter. Individual that wish to register for the company's earnings conference call can do so using this link.

Bionano Genomics Stock Performance

Bionano Genomics stock opened at $1.35 on Tuesday. The business has a 50 day moving average of $1.61 and a 200-day moving average of $1.98. Bionano Genomics has a 1 year low of $1.16 and a 1 year high of $4.35. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.51 and a quick ratio of 5.77. The company has a market capitalization of $400.84 million, a P/E ratio of -3.29 and a beta of 2.30.

Wall Street Analyst Weigh In

BNGO has been the topic of several analyst reports. BTIG Research  reiterated a "buy" rating and issued a $3.50 target price on shares of Bionano Genomics in a report on Monday, December 12th. Oppenheimer cut their price target on Bionano Genomics from $12.00 to $9.00 and set an "outperform" rating on the stock in a report on Monday, February 6th. Finally, Scotiabank started coverage on Bionano Genomics in a report on Wednesday, January 4th. They set a "sector outperform" rating and a $4.00 price target on the stock.

Institutional Investors Weigh In On Bionano Genomics

Several large investors have recently made changes to their positions in the business. Virtu Financial LLC increased its position in shares of  Bionano Genomics by 299.2% during the 4th quarter. Virtu Financial LLC now owns 258,591 shares of the company's stock valued at $378,000 after purchasing an additional 193,819 shares during the last quarter.  Verition Fund Management LLC bought a new position in shares of  Bionano Genomics during the 4th quarter worth $44,000.  Alpine Global Management LLC grew its stake in shares of  Bionano Genomics by 242.6% during the 4th quarter. Alpine Global Management LLC now owns 54,477 shares of the company's stock worth $80,000 after acquiring an additional 38,577 shares during the period.  Engineers Gate Manager LP bought a new position in shares of  Bionano Genomics during the 4th quarter worth $73,000.  Finally, Charles Schwab Investment Management Inc. grew its stake in shares of  Bionano Genomics by 3.8% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 2,199,429 shares of the company's stock worth $3,211,000 after acquiring an additional 79,801 shares during the period. 26.91% of the stock is owned by hedge funds and other institutional investors.

Bionano Genomics Company Profile

Bionano Genomics, Inc is a life sciences instrumentation company, which focuses on the genome analysis space. The firm engages in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline cytogenetics.